Mankind Pharma inks exclusive insulin licensing deal
Mankind Pharma inks exclusive insulin licensing deal for Insulin Degludec and its combination in India. The agreement boosts its diabetes portfolio with potential for future revenue growth. No financial terms were disclosed. This strategic move enhances its presence in the chronic care segment.
📊 STOCKS: $MANKIND | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Pharma
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Next articleibc recovery rates rise in q1fy27